Recursion Pharmaceuticals, Inc. RXRX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $665.18M+30.6% | $753.92M+25.0% | $667.15M+53.1% | $533.85M+10.6% | $509.16M+66.3% | ||
| $709.56M+21.5% | $812.85M+13.8% | $714.11M+50.6% | $587.16M+12.4% | $584.15M+70.0% | ||
| $95.81M-24.5% | $103.93M-26.3% | $111.71M+32.3% | $120.04M+43.5% | $126.83M+46.3% | ||
| $160.17M+1.3% | $162.16M+8.9% | $162.04M+211% | $164.27M+216% | $158.11M+204% | ||
| $294.07M-12.4% | $309.9M-7.7% | $322.34M+845% | $341.32M+793% | $335.79M+946% | ||
| $1.34B+2.6% | $1.47B+1.8% | $1.4B+92.6% | $1.3B+67.9% | $1.31B+134% | ||
| $71.72M+36.0% | $76.45M+133% | $79.95M+430% | $68.27M+299% | $52.72M+242% | ||
| $32.79M-17.3% | $37.61M-39.1% | $47.36M-4.5% | $39.69M+23.2% | $39.65M+8.3% | ||
| $9.27M+7.9% | $9.09M— | $8.92M— | $8.75M— | $8.59M— | ||
| $129.7M-8.7% | $147.71M-21.2% | $155.1M+42.4% | $164.03M+90.5% | $141.98M+92.1% | ||
| $7.18M-56.3% | $9.56M-49.7% | $11.9M-42.0% | $14.2M-38.1% | $16.45M+1,436% | ||
| $314.75M-15.2% | $343.27M-17.0% | $352.58M+74.6% | $383.21M+100% | $371.29M+137% | ||
| 2B0.0% | 2B+49,999,900% | 2B0.0% | 2B0.0% | 2B0.0% | ||
| -$2.19B-34.3% | -$2.08B-45.0% | -$1.97B-57.1% | -$1.81B-56.1% | -$1.63B-54.3% | ||
| $1.02B+9.7% | $1.13B+9.3% | $1.05B+99.6% | $919.15M+57.3% | $933.95M+133% | ||
| $1.34B+2.6% | $1.47B+1.8% | $1.4B+92.6% | $1.3B+67.9% | $1.31B+134% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Recursion Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Recursion Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.